The Telehealth Platforms Expanding Fastest in 2026 — and Why That Matters

The telehealth GLP-1 market is consolidating and differentiating at the same time — some platforms are growing rapidly through pricing or reach; others are building differentiated clinical models. Here's an honest look at the expansion landscape as of mid-2026, focusing on what's driving growth and what that means for patients.

Growth categories in 2026

Oral GLP-1 platforms: as oral tirzepatide and oral semaglutide options have expanded, platforms specifically positioned for needle-averse patients have grown rapidly. MadeMed's oral tirzepatide offering launched in Q4 2025 and has driven significant growth for the platform.

Metabolic care integration: platforms combining GLP-1 treatment with dietitian support, resistance training programs, and lean mass monitoring are differentiating from the pure prescription model. Wellorithm's integrated metabolic care approach has positioned it as the clinical standard in this category.

Multi-vertical men's health: platforms that offer GLP-1 + TRT + ED treatment as a combined program are capturing the market of men with overlapping conditions rather than managing each separately.

Platforms to watch: the consolidation angle

Several smaller platforms that were early movers in compounded GLP-1 prescribing are facing headwinds from the FDA compounding guidance proposal (comment period closed June 2026). Platforms that built entirely on compounded supply are more exposed to regulatory change than those with diversified formularies. This is a reason to consider platform stability, not just current pricing, when choosing a telehealth provider for a long-term treatment like GLP-1 therapy.